Antiviral Drug News and Research

RSS

Bioniche receives European patent

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had an additional European patent granted by the European Patent Office (EPO) on its core mycobacterial cell wall technology.

29 Mar 2005

Strawberries destroy cancer cells

Researchers specializing in the health benefits of plant compounds have shown that quercetin, a phytonutrient found in abundance in strawberries and other fruits, can induce programmed self-destruction of human cancer cells.

23 Mar 2005

New findings about the spread of HIV in the UK

Contrary to the prevailing belief that the HIV epidemic in the UK can be traced back to one source, a new study by Oxford and London scientists suggests that HIV spread via at least six independent virus introductions and subsequent transmission chains.

21 Mar 2005

HIV-1 spread through six transmission lines in the UK

Contrary to the prevailing belief that the HIV epidemic in the UK can be traced back to one source, a new study suggests that HIV spread via at least six independent virus introductions and subsequent transmission chains.

14 Mar 2005

St. John's wort increases effectiveness of Plavix

The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds.

6 Mar 2005

alpha-defensin-1, a protein found in immune cells, can control HIV infection

Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.

1 Mar 2005

Study first to document increase risk of herpes infection due to oral sex, particularly in young women

The first clinical study to document risk of acquiring herpes simplex virus type 1 infection based on sexual activity has linked oral sex and vaginal intercourse with a demonstrably higher rate of infection, particularly in young women, researchers from the University of Pittsburgh report in the February issue of Sexually Transmitted Diseases, the journal of the American Sexually Transmitted Diseases Association.

28 Feb 2005

Project targeting the increasing resistance of some viruses to drugs

A new project targeting the increasing resistance of some viruses to drugs is being funded with the help of nine million euros under the Life Sciences, Genomics and Biotechnology for Health area of the EU’s Framework Programme.

28 Feb 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Gel provides protection from HIV and herpes

Mount Sinai School of Medicine researchers demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex Virus. The study, presented at the 12th Conference on Retroviruses and Opportunistic Infections, is the first to show that a gel can retain anti-viral activity within the human vagina.

27 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005

New 3-DCR HIV strain does not respond to three classes of anti-retroviral medication

A highly resistant strain of rapidly progressive human immunodeficiency virus (HIV) has been diagnosed for the first time in a New York City resident who had not previously undergone antiviral drug treatment, according to the Department of Health and Mental Hygiene (DOHMH).

13 Feb 2005

Many alcohol dependent HIV patients need assistance adhering to medications

Supervised medication delivery or simplified dosing regimens may be needed to ensure that HIV-infected patients with a history of alcohol problems stick to their medication regimens, according to a new study by researchers at Boston University Medical Center.

8 Feb 2005

Researchers attack cervical cancer

As more and more promising results of clinical trials on vaccination against human papillomaviruses are published, the more likely it becomes that an HPV vaccine will be the first licensed immunization against a sexually transmitted disease.

17 Jan 2005

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Potential cure for lymphoma in HIV patients

Stem cell transplants have become the standard of care for patients with relapsed lymphoma, but not for patients who suffer from both this disease and HIV.

7 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

DermaVir, a novel treatment for HIV/AIDS, complements and improves present drug therapies

DermaVir, a novel treatment for HIV/AIDS, offers a new option which complements and improves present drug therapies. The vaccine, applied topically to the skin, has demonstrated efficacy in boosting immune responses and controlling virus replication in chronically infected monkeys.

6 Jan 2005

Herpes virus is everywhere and it's unavoidable

While not the first, the researchers report that this study uses the most sensitive techniques in a cross-sectional assessment performed to date of the presence of HSV-1 DNA in the eyes and mouths of healthy individuals, in terms of population size and total samples collected.

6 Jan 2005

AIDS breakthrough - vaccine strengthens the body’s immune system againts HIV

A Hadassah University Medical Center research team has developed a vaccine that significantly strengthens the body’s immune system against the autoimmune sequela of HIV infection, a breakthrough that could dramatically make an impact in the treatment of AIDS patients.

28 Dec 2004